Latrive J P, Barbare J C, Darchis J P, Hercelin B, Rosembaum M
Service de Gastroentérologie, Centre Hospitalier de Compiègne.
Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):707-10.
The cefotiam (CFT) penetration in infected ascitic fluid was investigated in 12 cirrhotic patients. CFT (1 g every 8 h) was given intravenously and measured by HPLC in plasmatic and ascitic samples. The mean ascitic concentrations (+/- SEM), 1 h, 3 h and 8 h after the first injection (J1) were 14.6 +/- 4.6, 11.8 +/- 3 and 8.4 +/- 2.9 micrograms/ml respectively. These values were 38, 62 and 88% of the corresponding mean plasmatic concentrations and higher than the MIC's for the organisms most commonly involved. The mean plasmatic and ascitic concentrations, a few days later (4.5 or 6 days) (Jn) were not significantly different from the corresponding values at J1. A significant decrease of polymorphonuclear cell count was observed between J1 and Jn. These results suggest that CFT diffusion into ascitic fluid is independent of inflammation and CFT is an adequate antibiotic in cirrhotic patients with infected ascitic fluid.
在12例肝硬化患者中研究了头孢替安（CFT）在感染性腹水中的渗透情况。静脉给予CFT（每8小时1 g），并通过高效液相色谱法测定血浆和腹水样本中的药物浓度。首次注射（J1）后1小时、3小时和8小时的平均腹水浓度（±标准误）分别为14.6±4.6、11.8±3和8.4±2.9μg/ml。这些值分别为相应平均血浆浓度的38%、62%和88%，且高于最常见相关微生物的最低抑菌浓度。几天后（4.5或6天）（Jn）的平均血浆和腹水浓度与J1时的相应值无显著差异。在J1和Jn之间观察到多形核细胞计数显著下降。这些结果表明，CFT向腹水中的扩散与炎症无关，CFT是治疗感染性腹水的肝硬化患者的一种合适抗生素。
